A diversified neuro-oncology pipeline is advancing, with TLX101-Tx showing strong safety and efficacy in clinical trials and TLX101-Px offering high diagnostic accuracy. Ongoing global trials target significant unmet needs in glioblastoma, positioning the portfolio for leadership in the field.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.